Wolfe Research initiated coverage of Neurocrine (NBIX) with an Outperform rating and $160 price target The firm launched coverage of the neuroscience biotech sector with a “portfolio of high conviction names across multiple therapeutic areas.” Wolfe believes the Inflation Reduction Act on Neurocrine’s Ingrezza should be modest. It says this already priced into the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target lowered to $140 from $169 at Truist
- Neurocrine post-earnings selloff overdone, says JPMorgan
- Neurocrine Biosciences Earnings Call Highlights Growth Momentum
- Neurocrine price target lowered to $177 from $180 at RBC Capital
- Neurocrine price target lowered to $185 from $187 at Needham